Nurix Appoints Nancy Pryer, Ph.D., Chief Development Officer
SAN FRANCISCO, May 8, 2018 – Nurix, Inc., a private drug discovery company, today announced the appointment of Dr. Nancy
News
News
News
Nurix Appoints Dr. Robert Tjian to its Board of Directors
SAN FRANCISCO, December 6, 2016 – Nurix, Inc., a private drug discovery company, today announced the appointment of Dr. Robert
News
Nurix Announces New Appointments to its Board of Directors
David Lacey, M.D., and Perry Karsen Appointed to Board of DirectorsTim Kutzkey, Ph.D., Appointed as Chairman of the Board SAN
News
Nurix Strengthens Executive Leadership Team
Pierre Beaurang, Ph.D., Promoted to Chief Business Officer Hans van Houte Joins Company as Vice President of Finance SAN FRANCISCO,
News
Celgene and Nurix Announce Collaboration Targeting Protein Homeostasis for Next-Generation Therapies in Oncology, Inflammation and Immunology
Celgene and Nurix Announce Collaboration Targeting Protein Homeostasis for Next-Generation Therapies in Oncology, Inflammation and Immunology SAN FRANCISCO, September 16,
News
Nurix Launches Collaboration with Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute to Expand its Drug Discovery Program
Nurix Partners with Senior Investigator Dr. Frank Sicheri, a Leader in E2 Ubiquitin Conjugating Enzyme Field, to Enhance its Protein
News
Nurix, Inc. Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer
Nurix Expands Leadership Team with Appointment of Pierre Beaurang, Ph.D., as Vice President, Business and Corporate Development SAN FRANCISCO–(BUSINESS WIRE)–Nurix,
News
Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway
Company Brings Together Leaders in Ubiquitin-Proteasome Research to Discover and Develop Small Molecules with Broad Therapeutic Potential SAN FRANCISCO &